125756-95-8

Basic information

• Product Name: 4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE
• Synonyms: 4-BROMO-3-ETHOXYANILINE HCL;4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE;4-bromo-3-ethoxyaniline;Benzenamine, 4-bromo-3-ethoxy- (9CI);3-ETHOXYANILINE-4-BROMOHCL;3-ETHOXY-4-BROMO ANILINE
• CAS NO: 125756-95-8
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 252.54
• Product Categories: ETHOXY;Fluorobenzene;Aniline;Miscellaneous;Anilines, Amides & Amines;Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds
• Mol File: 125756-95-8.mol

Chemical Properties

• Boiling Point: 286.4 °C at 760 mmHg
• Flash Point: 127 °C
• Appearance: /
• Density: 1.455 g/cm³
• Vapor Pressure: 0.000243mmHg at 25°C
• PKA: 3.52±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE(125756-95-8)
• EPA Substance Registry System: 4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE(125756-95-8)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36
• Hazardous Substances Data: 125756-95-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-ETHOXYANILINE HYDROCHLORIDE is used as a reactant for the preparation of anilinoquinolinecarboxamides, which are known as CSF-1R kinase inhibitors. These inhibitors play a crucial role in the development of targeted therapies for various diseases, including cancer, by modulating the activity of specific cellular signaling pathways.

InChI:InChI=1/C8H10BrNO.ClH/c1-2-11-8-5-6(10)3-4-7(8)9;/h3-5H,2,10H2,1H3;1H

Upstream product

• 554-84-7 meta-nitrophenol 
• 52427-05-1 2-bromo-5-nitrophenol 
• 423165-33-7 1-bromo-2-ethoxy 4-nitrobenzene 

Downstream Products

• 1352619-74-9 N-[4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide 
• 1352620-17-7 4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[1,2,4]triazolo-[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide 
• 1600515-58-9 C₁₉H₁₆BrN₃O 
• 850727-45-6 C₁₁H₁₁BrN₄O₂ 
• 1041853-51-3 1-(2-amino-5-bromo-4-ethoxyphenyl)ethanone 
• 1041853-22-8 6-bromo-7-ethoxy-4-hydroxycinnoline-3-carboxylic acid 

Relevant articles and documents

LACTAMS AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to substituted triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as tumours and proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.

SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to substituted triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.